title: Calpain-mediated AQP2 proteolysis in inner medullary collecting duct.
abstract: Vitamin D-elicited hypercalcemia/hypercalciuria is associated with polyuria in humans and in animal models. In rats, dihydrotachysterol (DHT) induces AQP2 water channel downregulation despite unaltered AQP2 mRNA expression and thus we investigated the mechanism of AQP2 degradation. Incubation of AQP2-containing inner medullary collecting duct (IMCD) endosomes with Ca(2+) or calpain elicited AQP2 proteolysis, an effect abolished by leupeptin. This endogenous, Ca(2+)-sensitive protease activity exhibited a different proteolytic digest pattern from trypsin, which also degraded AQP2 in vitro. IMCDs contain abundant micro-calpain protein and functional calpain proteolytic activity as demonstrated by immunohistochemistry, immunoblotting, and gel zymography. Furthermore, by small particle flow cytometry we demonstrated that micro-calpain colocalizes with apical IMCD endosomes. DHT does not appear to elicit general proteolysis, however, in addition to AQP2 degradation, DHT treatment also diminished micro-calpain and calpastatin expression although whether these changes contributed to the AQP2 instability remains unclear. Together, these data show for the first time that AQP2 is a substrate for calpain-mediated proteolysis and that furthermore, micro-calpain, like AQP2, is both highly expressed in renal inner medulla and localized to apical IMCD endosomes.
authors.affiliation: Division of Nephrology, Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
authors.forename: Dechu P
authors.initials: DP
authors.lastname: Puliyanda
authors.forename: Donald T
authors.initials: DT
authors.lastname: Ward
authors.forename: Michelle A
authors.initials: MA
authors.lastname: Baum
authors.forename: Timothy G
authors.initials: TG
authors.lastname: Hammond
authors.forename: H William
authors.initials: HW
authors.lastname: Harris
mesh_terms: D000818:Animals; D051399:Aquaporin 2; D051403:Aquaporin 6; D020346:Aquaporins / Q000737:chemistry* / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D002135:Calcium-Binding Proteins / Q000378:metabolism; D002154:Calpain / Q000378:metabolism / Q000494:pharmacology*; D002364:Caseins / Q000378:metabolism; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D003911:Dextrans / Q000378:metabolism; D004097:Dihydrotachysterol / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D011992:Endosomes / Q000378:metabolism; D005434:Flow Cytometry; D015151:Immunoblotting; D007150:Immunohistochemistry; D007685:Kidney Tubules, Collecting / Q000378:metabolism*; D007976:Leupeptins / Q000494:pharmacology; D008297:Male; D011485:Protein Binding; D051381:Rats; D017207:Rats, Sprague-Dawley; D014357:Trypsin / Q000494:pharmacology
chemical_list: C496025:Aqp2 protein, rat; D051399:Aquaporin 2; D051403:Aquaporin 6; D020346:Aquaporins; D002135:Calcium-Binding Proteins; D002364:Caseins; D015853:Cysteine Proteinase Inhibitors; D003911:Dextrans; D007976:Leupeptins; C033668:calpastatin; D014357:Trypsin; D002154:Calpain; C449002:mu-calpain; C032854:leupeptin; D004097:Dihydrotachysterol; D002118:Calcium